Molecular Hydrogen Inhibits Colorectal Cancer Growth via the AKT/SCD1 Signaling Pathway.

The publication “Molecular Hydrogen Inhibits Colorectal Cancer Growth via the AKT/SCD1 Signaling Pathway.” is organized in H2HUBB under the research focus molecular hydrogen cancer supportive study 2022 zhang. The publication is cited as Zhang X, Tao G, Zhao Y, Xing S, Jiang J, Liu B, Qin S, BioMed research international, 2022. This uncontrolled human study examined Molecular Hydrogen Inhibits Colorectal Cancer Growth via the AKT/SCD1 Signaling Pathway. The abstract describes Human participants. The abstract reports: This study demonstrates that high concentrations of H exert an inhibitory effect on CRC by inhibiting the pAKT/SCD1 pathway. Further studies are warranted for…. This is an automated editorial draft based on the abstract and requires source review before publication.

Molecular hydrogen cancer supportive study 2022 zhang overview

Molecular hydrogen (H) has been considered a potential therapeutic target in many cancers. Therefore, we sought to assess the potential effect of H on… Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.

Study design and hydrogen intervention

Publication type: Uncontrolled human study. Evidence type: Human clinical evidence. Research model or population: Human participants. Blinding: Unknown. Control status: Unknown.

Delivery method: Other or not reported.

Reported findings and scientific interpretation

For this molecular hydrogen cancer supportive study 2022 zhang, the study record reports the following: The abstract reports: This study demonstrates that high concentrations of H exert an inhibitory effect on CRC by inhibiting the pAKT/SCD1 pathway. Further studies are warranted for…

These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.

How this research record was prepared

H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.

Limitations, safety, and original source

Limitations: Further studies are warranted for clinical evaluation of H as SCD1 inhibitor to target CRC.

Safety: The abstract did not provide detailed safety or adverse-event information.

This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.